Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
Summary
Vertex Pharmaceuticals Incorporated reported strong financial results for the fourth quarter and full year ended December 31, 2025, via Ex. 99.1 press release. Full year 2025 total revenue reached $12.0 billion, a 9% increase compared to full year 2024, with fourth quarter total revenue at $3.19 billion, up 10% from . The company also provided full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, expecting non-CF products to contribute $500 million or more. Additionally, Vertex is on track to complete the BLA filing for U.S. accelerated approval of povetacicept in IgAN in the first half of 2026.
Why It Matters
Investors should note the strong 9% full year revenue growth to $12.0 billion and the positive 2026 revenue guidance of $12.95 billion to $13.1 billion, indicating continued financial strength and future growth. This guidance includes a significant expected contribution from non-CF products and highlights ongoing pipeline advancements like the povetacicept BLA filing.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how VRTX traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View VRTX Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“On February 12, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and twelve months ended December 31, 2025.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000875320
- Filing Date
- Thursday, February 12, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive